Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 167Leukemia 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 71Lymphoma 51Myelodysplastic Syndromes 38Congenital Abnormalities 32Burkitt Lymphoma 29Lymphoma, Non-Hodgkin 27Recurrence 26Leukemia, Myelomonocytic, Acute 26Leukemia, Monocytic, Acute 26Lymphoma, Mantle-Cell 23Leukemia, Erythroblastic, Acute 23Leukemia, Megakaryoblastic, Acute 21Hodgkin Disease 18Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 13Myeloproliferative Disorders 12Leukemia, Myelomonocytic, Chronic 11Leukemia, Biphenotypic, Acute 11Leukemia, Eosinophilic, Acute 9Blast Crisis 9Lymphoma, B-Cell 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Anemia, Refractory, with Excess of Blasts 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 7Multiple Myeloma 7Leukemia, Basophilic, Acute 7Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

Rituximab 4Cyclophosphamide 4ponatinib 2Vorinostat 2Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2Bortezomib 2tetulomab tetraxetan lu-177 1pembrolizumab 1ibrutinib 1ibritumomab tiuxetan 1fludarabine 1durvalumab 1cobomarsen 1acalabrutinib 1Melphalan 1Lutetium 1Lenalidomide 1KW-2478 1Imatinib Mesylate 1Ifosfamide 1Hsp90 inhibitor KU757 1Cytarabine 1Carmustine 1Carboplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Immune System Diseases × Cytarabine × Clear all
NCT02366663 2018-03-12

SPINOZA

City of Hope Medical Center

Phase 3 Terminated
3 enrolled 8 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡